- Conditions
- Obesity, Overweight
- Interventions
- Bimagrumab, Tirzepatide, Bimagrumab Placebo, Tirzepatide Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 12
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Walnut Creek, California + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 697–720
of 1,451
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Type 2 Diabetes
- Interventions
- Autoimmune Antibody Assays
- Diagnostic Test
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Twinsburg, Ohio
- Conditions
- Alzheimer Disease, Dementia, Medication Adherence, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- HiDO-ALZ
- Device
- Lead sponsor
- HiDO Technologies
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Dutogliptin, Placebo
- Drug
- Lead sponsor
- Forest Laboratories
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 677 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 98
- States / cities
- Birmingham, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 84 more
- Conditions
- Disparities, Community Health Workers, Cardiovascular Diseases, Social Determinants of Health (SDOH)
- Interventions
- DECIDE, Community Health Worker Support
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 35 Years to 75 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Diabetes Mellitus, Type 1 Diabetes, Type 2 Diabetes
- Interventions
- RIGHTEST Continuous Glucose Monitoring System
- Device
- Lead sponsor
- Bionime Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 13
- States / cities
- Guntersville, Alabama • Tucson, Arizona • Canoga Park, California + 10 more
- Conditions
- Type 1 Diabetes
- Interventions
- Mini-glucagon, Remote monitoring, Carbohydrates
- Drug · Device · Dietary Supplement
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 7 Years to 21 Years
- Enrollment
- 57 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Diabetes, Depression
- Interventions
- Medication Care Management (MCM), Cognitive-Behavioral Therapy (CBT)
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 21 Years to 80 Years
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2011
- U.S. locations
- 3
- States / cities
- Ann Arbor, Michigan • Grand Blanc, Michigan
- Conditions
- Macular Edema, Diabetic
- Interventions
- Ranibizumab, Placebo, PF-04634817, Masked Sham Therapy
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 199 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 33
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Arcadia, California + 25 more
- Conditions
- Diabetes Mellitus, Type II
- Interventions
- Type 2 Diabetes Self-Management
- Behavioral
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Type 1 Diabetes, Hyperglycemia, Postprandial
- Interventions
- Insulin
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Type 2 Diabetes
- Interventions
- Empagliflozin 25 MG
- Drug
- Lead sponsor
- The University of Texas Health Science Center at San Antonio
- Other
- Eligibility
- 30 Years to 75 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Obese, Overweight, Miscarriage, Recurrent Pregnancy Loss
- Interventions
- Structured Weight Loss Program, Routine Weight Loss Counseling
- Behavioral
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 39 Years · Female only
- Enrollment
- 7 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glargine insulin, NPH insulin and regular insulin, lispro insulin
- Drug
- Lead sponsor
- Cook County Health
- Government
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Hypertensive Heart Disease, Hypertension
- Interventions
- More intensive CHW Intervention, Less Intensive CHW Intervention
- Behavioral
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 25 Years
- Enrollment
- 1,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2016
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hyperglycemia
- Interventions
- Glucommander-Guided Intravenous Insulin Infusion, Standard Intravenous Insulin Infusion, Simple Calculated Intravenous Insulin Infusion
- Procedure
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 3
- States / cities
- Chicago Heights, Illinois • Albuquerque, New Mexico
- Conditions
- Type 1 Diabetes
- Interventions
- Bionic Pancreas, Usual Care
- Device · Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 6 Years to 11 Years
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- 2.5 mg Saxagliptin tablet, 5 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR, 5 mg saxagliptin, 10 mg dapagliflozin / 1000 mg metformin XR tablet, Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Peripheral Arterial Disease, Diabetes Mellitus
- Interventions
- Self-managed walking, Control group
- Behavioral · Other
- Lead sponsor
- University of Kansas
- Other
- Eligibility
- 40 Years and older
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Wichita, Kansas
- Conditions
- Type 1 Diabetes, Eating Disorders
- Interventions
- Diabetes Body Project, Educational Group
- Behavioral
- Lead sponsor
- Oslo University Hospital
- Other
- Eligibility
- 14 Years to 35 Years
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 2
- States / cities
- Stanford, California • Boston, Massachusetts
- Conditions
- Chronic Kidney Disease
- Interventions
- AZD4248, Placebo, Midazolam, Metformin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 192 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 5
- States / cities
- Glendale, California • Chicago, Illinois • Ann Arbor, Michigan + 2 more
- Conditions
- Diabetes, Aging
- Interventions
- Telehealth for Diabetes Self Management, Telehealth for Diabetes Self Management
- Behavioral · Other
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2007
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Diabetes Mellitus
- Interventions
- Diabetes Management Questionnaire
- Other
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Type 1 Diabetes, Diabetes Mellitus, Type 1
- Interventions
- CELZ-201 Administration, Control Group
- Biological · Other
- Lead sponsor
- Creative Medical Technology Holdings Inc
- Industry
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Miami, Florida